insights_auto
Why is ADAPY down २.६३%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$ ०.०३७
arrow_downward
-२.६३%(-०.००१००) 1D
अक्टोबर २, १६:००:०० GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
US$ ०.०२
High
US$ ०.०४
Low
US$ ०.०२
Mkt. cap
९३.१७ लाख
Avg. vol.
२.०९ लाख
Volume
६४.७५ हजार
52-wk high
US$ ०.२८
52-wk low
US$ ०.००
Beta
०.७५
Shares outstanding
२६.५१ करोड
No. of employees
२७२
Open
US$ ०.०२
High
US$ ०.०४
Low
US$ ०.०२
Mkt. cap
९३.१७ लाख
Avg. vol.
२.०९ लाख
Volume
६४.७५ हजार
52-wk high
US$ ०.२८
52-wk low
US$ ०.००
Beta
०.७५
Shares outstanding
२६.५१ करोड
No. of employees
२७२
News stories
From web sources and news partners
Business Wire
·
८ मिनेट पहिले
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Intellia Therapeutics
·
१ घण्टा पहिले
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
·
५३ मिनेट पहिले
NeuroSense Provides Update on Nasdaq Listing Compliance
Investor's Business Daily
·
१८ मिनेट पहिले
Nasdaq Pops After Jobs Report; Arrow, Materion, Advantest In Focus
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR